CLDI (Calidi Biotherapeutics) Interest Expense: $-0.17 Mil (TTM As of Mar. 2026)


CLDI Calidi Biotherapeutics Inc CLDI
12 GF Score
Price $0.15
! 1 Warning Sign
View Full Analysis

What is Calidi Biotherapeutics Interest Expense?

Calidi Biotherapeutics CLDI -5.70% 12 Interest Expense is $-0.17 Mil as of Mar. 2026. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Calidi Biotherapeutics's interest expense for the three months ended in Mar. 2026 was $ -0.04 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.17 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Calidi Biotherapeutics's Operating Income for the three months ended in Mar. 2026 was $ -4.19 Mil. Calidi Biotherapeutics's Interest Expense for the three months ended in Mar. 2026 was $ -0.04 Mil. Calidi Biotherapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Calidi Biotherapeutics  (AMEX:CLDI) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Calidi Biotherapeutics's Interest Expense for the three months ended in Mar. 2026 was $-0.04 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-4.19 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0.75 Mil.

Calidi Biotherapeutics's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Calidi Biotherapeutics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Calidi Biotherapeutics Interest Expense Historical Data

* Premium members only.

The historical data trend for Calidi Biotherapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Calidi Biotherapeutics Interest Expense Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.61 -0.16 -1.07 -0.93 -0.21

Calidi Biotherapeutics Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.05 -0.04 -0.04 -0.04
CLDI
12GF Score
Calidi Biotherapeutics Inc CLDI
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Calidi Biotherapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.17 Mil mean?
Calidi Biotherapeutics (CLDI) has a Interest Expense of $-0.17 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Calidi Biotherapeutics and its competitors.
Is Calidi Biotherapeutics' Interest Expense too high?
Calidi Biotherapeutics' current Interest Expense is $-0.17 Mil. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' Interest Expense compare to DCOY and CDT?
Calidi Biotherapeutics' Interest Expense of $-0.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Calidi Biotherapeutics and its competitors. Calidi Biotherapeutics's current Interest Expense is $-0.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current Interest Expense of $-0.17 Mil. The current Interest Expense is $-0.17 Mil. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current Interest Expense is $-0.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Calidi Biotherapeutics Business Description

Address 4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score

Get the complete analysis for CLDI

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price